Loading stock…

Agios Pharmaceuticals, Inc. (AGIO) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Agios Pharmaceuticals, Inc.

AGIOMarket cap $1.90BPrice $31.8

Country🇺🇸United States

SectorHealthcare

IndustryBiotechnology

Develops medicines for rare diseases by targeting cellular metabolism, the same science that led to the first-ever approved treatment for sickle cell disease's underlying cause, not just its symptoms.

In Bastion Portfolios?

52W Return-25%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+56%10

Revenue Forecast

Rev CAGR (1y)+233%10

Rev CAGR (3y)+107%10

Rev CAGR (5y)+70%10

Earnings Forecast

EPS Growth Y+1Loss1

EPS Growth Y+2Loss1

EPS Growth Y+3Loss1

Quality

Margins

EBIT Margin-467%1

Net Income Margin-418%1

Free Cash Flow Margin-371%1

Debt

Net Debt/EBITDAna–

Efficiency

ROE-34%1

ROA-32%1

Earnings Stabilityna–

GEAR+VERY WEAK10

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)na–

P/E Ratio (Forward 3y)na–

P/BV1.87

EV Multiples

EV/EBITDA Fwdna–

EV/EBIT Fwdna–

Yield

Free Cash Flow Yield-19.2%1

Dividend Yieldna–

Momentum

Short term

1 month return-5%5

3 month return-26%1

YTD return+17%7

Mid term

Price vs 52wHigh69%3

1 year return-25%2

Long term

3 year return+32%5

5 year return-28%2

Risk Shield

Price Risk

Beta1.91

Volatility91%1

Free Cash Flow

Free Cash Flow Margin-371%1

Free Cash Flow Yield-19.2%1

Quality

ROCE-38%1

Earnings Stabilityna–

Net Debt/EBITDAna–

02Growth

Is it actually growing, and how fast?

AGIOAgios Pharmaceuticals

Revenue FY25$54M

GROWTH RATING↗

VERY STRONG89 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+56%10

Revenue, next 1Y+233%10

Revenue, next 3Y, CAGR+107%10

Revenue, next 5Y, CAGR+70%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

It out-grows 89% of companies worldwide.

Revenue grew 56%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 107%/yr over the next 3 years, ahead of most of the market.10/10

Revenue grew 56%/yr over the last 3 years and is set to grow 107%/yr from here.

The runway holds up: revenue is set to grow 70%/yr over five years.10/10

WATCH

None flagged.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that's speeding up. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY WEAK11 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-5%5

3-month return-26%1

YTD return+17%7

MID & LONG-TERM▾SCORE

% of 52-week high69%3

1-year return-25%2

3-year return+32%5

5-year return-28%2

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming so far this year (+17%).

WATCH

Returns sit at the market level over the past month (-5%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+32% over three years and -28% over five), behind 60% of the market.

It's down 25% over the past year, now 31% below its 52-week high. That is lagging the market.

The stock is underperforming over three months (-26%).

BOTTOM LINE

Falling Knife

Returns rank poorly over both the short and long run, and the price is still falling. Momentum is firmly negative — catching this is a bet against the tape, not with it. Wait for a base to form. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Agios Pharmaceuticals, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

AGIOAgios Pharmaceuticals

Revenue FY25$54M

GROWTH RATING↗

VERY STRONG89 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+56%10

Revenue, next 1Y+233%10

Revenue, next 3Y, CAGR+107%10

Revenue, next 5Y, CAGR+70%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

It out-grows 89% of companies worldwide.

Revenue grew 56%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 107%/yr over the next 3 years, ahead of most of the market.10/10

Revenue grew 56%/yr over the last 3 years and is set to grow 107%/yr from here.

The runway holds up: revenue is set to grow 70%/yr over five years.10/10

WATCH

None flagged.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that's speeding up. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY WEAK11 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-5%5

3-month return-26%1

YTD return+17%7

MID & LONG-TERM▾SCORE

% of 52-week high69%3

1-year return-25%2

3-year return+32%5

5-year return-28%2

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming so far this year (+17%).

WATCH

Returns sit at the market level over the past month (-5%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+32% over three years and -28% over five), behind 60% of the market.

It's down 25% over the past year, now 31% below its 52-week high. That is lagging the market.

The stock is underperforming over three months (-26%).

BOTTOM LINE

Falling Knife

04Value

Are you paying a fair price for it?

Stop guessing on Agios Pharmaceuticals, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community